Concepts (108)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Microenvironment | 3 | 2014 | 556 | 0.440 |
Why?
|
| Melanoma, Experimental | 2 | 2013 | 111 | 0.410 |
Why?
|
| Radiosurgery | 2 | 2015 | 318 | 0.360 |
Why?
|
| Neoplasms | 4 | 2015 | 3242 | 0.360 |
Why?
|
| Neoplasms, Experimental | 4 | 2019 | 269 | 0.320 |
Why?
|
| Interferon Type I | 1 | 2011 | 171 | 0.310 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2016 | 667 | 0.300 |
Why?
|
| Inflammation | 1 | 2013 | 1063 | 0.260 |
Why?
|
| Radiotherapy | 3 | 2019 | 325 | 0.250 |
Why?
|
| Immunotherapy | 3 | 2019 | 766 | 0.200 |
Why?
|
| Immunity, Innate | 3 | 2014 | 464 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2019 | 157 | 0.160 |
Why?
|
| B7-H1 Antigen | 3 | 2016 | 306 | 0.130 |
Why?
|
| Radiation Tolerance | 2 | 2019 | 176 | 0.130 |
Why?
|
| Cytokines | 2 | 2013 | 871 | 0.130 |
Why?
|
| Mice, Knockout | 5 | 2019 | 2160 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 7 | 2019 | 3483 | 0.120 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 23 | 0.110 |
Why?
|
| Animals | 12 | 2019 | 28901 | 0.110 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2013 | 188 | 0.110 |
Why?
|
| Nucleotidyltransferases | 1 | 2014 | 33 | 0.110 |
Why?
|
| Interferon-beta | 2 | 2014 | 126 | 0.110 |
Why?
|
| Vaccination | 1 | 2016 | 310 | 0.100 |
Why?
|
| Adaptive Immunity | 2 | 2014 | 180 | 0.100 |
Why?
|
| Mice | 9 | 2015 | 12525 | 0.100 |
Why?
|
| Bacterial Vaccines | 1 | 2013 | 45 | 0.100 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2013 | 72 | 0.100 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2013 | 218 | 0.090 |
Why?
|
| Cell Death | 1 | 2013 | 264 | 0.090 |
Why?
|
| Cancer Vaccines | 1 | 2013 | 170 | 0.090 |
Why?
|
| Antigens, Neoplasm | 1 | 2013 | 357 | 0.090 |
Why?
|
| Dendritic Cells | 2 | 2014 | 539 | 0.080 |
Why?
|
| Interferon-alpha | 1 | 2011 | 194 | 0.080 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2011 | 96 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 725 | 0.080 |
Why?
|
| Cell Line, Tumor | 4 | 2019 | 2776 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2014 | 487 | 0.080 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2009 | 16 | 0.070 |
Why?
|
| Signal Transduction | 3 | 2015 | 3581 | 0.070 |
Why?
|
| Lymphotoxin-beta | 1 | 2008 | 6 | 0.070 |
Why?
|
| DNA | 1 | 2014 | 1329 | 0.070 |
Why?
|
| Helicobacter Infections | 1 | 2009 | 38 | 0.070 |
Why?
|
| Gastric Mucosa | 1 | 2009 | 70 | 0.070 |
Why?
|
| Gastritis | 1 | 2009 | 39 | 0.070 |
Why?
|
| Lymphotoxin-alpha | 1 | 2008 | 43 | 0.070 |
Why?
|
| Liver Regeneration | 1 | 2008 | 36 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2011 | 325 | 0.070 |
Why?
|
| Interferon-gamma | 3 | 2019 | 462 | 0.070 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2009 | 151 | 0.070 |
Why?
|
| Membrane Proteins | 1 | 2014 | 1275 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2019 | 1741 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 1309 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2019 | 1642 | 0.050 |
Why?
|
| Radiation, Ionizing | 2 | 2014 | 124 | 0.050 |
Why?
|
| Cell Movement | 2 | 2019 | 816 | 0.050 |
Why?
|
| Antigen Presentation | 2 | 2013 | 229 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2015 | 1079 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2013 | 322 | 0.040 |
Why?
|
| Lymphocyte Activation | 2 | 2013 | 809 | 0.030 |
Why?
|
| Cell Proliferation | 2 | 2015 | 1753 | 0.030 |
Why?
|
| Humans | 4 | 2015 | 95992 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 1029 | 0.030 |
Why?
|
| Chemokines | 1 | 2016 | 77 | 0.030 |
Why?
|
| Receptors, CXCR3 | 1 | 2015 | 13 | 0.030 |
Why?
|
| Xanthones | 1 | 2014 | 11 | 0.030 |
Why?
|
| Nucleotides, Cyclic | 1 | 2014 | 12 | 0.030 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 22 | 0.030 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2014 | 52 | 0.030 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2014 | 58 | 0.030 |
Why?
|
| Cross-Priming | 1 | 2014 | 54 | 0.030 |
Why?
|
| RNA Interference | 1 | 2014 | 385 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1533 | 0.030 |
Why?
|
| Myeloid Cells | 1 | 2014 | 120 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2013 | 110 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2014 | 411 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 562 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1541 | 0.020 |
Why?
|
| Epitopes | 1 | 2013 | 258 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 443 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 725 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 477 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 1124 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 1347 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2014 | 2928 | 0.020 |
Why?
|
| Helicobacter felis | 1 | 2009 | 1 | 0.020 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2009 | 3 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 2009 | 82 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2009 | 38 | 0.020 |
Why?
|
| Lymphotoxin beta Receptor | 1 | 2008 | 28 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2009 | 246 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2008 | 89 | 0.020 |
Why?
|
| Interleukin-10 | 1 | 2009 | 166 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2009 | 283 | 0.020 |
Why?
|
| Piperidines | 1 | 2009 | 171 | 0.020 |
Why?
|
| Immune System | 1 | 2008 | 103 | 0.020 |
Why?
|
| Spleen | 1 | 2008 | 419 | 0.020 |
Why?
|
| Hepatectomy | 1 | 2008 | 178 | 0.020 |
Why?
|
| Apoptosis | 1 | 2014 | 1756 | 0.020 |
Why?
|
| Models, Animal | 1 | 2008 | 287 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 517 | 0.020 |
Why?
|
| Interleukin-6 | 1 | 2008 | 281 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2013 | 2534 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 712 | 0.010 |
Why?
|
| Time Factors | 1 | 2014 | 5593 | 0.010 |
Why?
|
| Liver | 1 | 2008 | 1231 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2385 | 0.010 |
Why?
|
| Female | 1 | 2013 | 49980 | 0.000 |
Why?
|
| Male | 1 | 2008 | 45792 | 0.000 |
Why?
|